diagnosis fields. The diagnosis of AF had previously been validated in a small randomly selected sample, with a high positive predictive value based upon medical chart review. 13 The first AF admission during the study period (index event) for patients aged 20-84 years who survived more than 28 days from admission was included in the analysis. We excluded 1882 patients who had mechanical heart valves (ICD codes: Supporting Information, table 1).
Outcomes
The outcome event date was defined as the date of hospital admission or date of death. Follow-up data for all patients, including coded cause of death, were available until 30 November 2013. Follow-up was censored at the date of the outcome event, 10 years after the index AF event, or 30 November 2013, whichever was earliest. Patients were followed up for between 28 days and 10 years from their index AF admission date.
Hospitalisations for stroke (ICD-10-AM codes I60-I64, H34.1) were identified in any discharge diagnosis field, and stroke deaths (ICD-10-AM codes I60-I69) in the underlying or multiple-code cause of death fields. The primary outcome was all stroke (stroke hospitalisation or stroke death). We defined non-fatal stroke as a stroke hospitalisation with survival longer than 28 days from admission; fatal strokes were any stroke death, irrespective of hospitalisation, or death from any cause within 28 days of hospitalisation for stroke. We also identified ischaemic strokes (first ischaemic stroke hospitalisation or death; ICD-10-AM codes I63, I64) and haemorrhagic strokes (first haemorrhagic stroke hospitalisation or death; ICD-10-AM codes I60-I62); 167 patients (more than 95% of whom were non-Aboriginal patients) had an ischaemic and haemorrhagic stroke and were included in both subtype analyses. Cardiovascular mortality (ICD-10-AM codes I00-I99) was identified from the underlying or associated causes of death.
Covariates
We used the "Getting our story right" algorithm to ascertain Aboriginal identity on the basis of data from multiple health datasets. 14 Comorbid conditions were identified from any diagnosis field in the 10 years of hospitalisation history preceding and including the index hospitalisation for AF, and included prior AF admission, stroke or transient ischaemic attack, coronary heart disease, myocardial infarction, valvular heart disease, chronic obstructive pulmonary disease, diabetes, and chronic kidney disease (Supporting Information, table 1). Charlson Comorbidity Index and CHA 2 DS 2 -VASc (stroke risk factors: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex) scores were calculated for each patient, based upon 10 years of hospitalisation history preceding and including the index AF admission (Supporting Information, table 1). 15 CHA 2 DS 2 -VASc scores of 2 or more indicate moderate to high risk of stroke, for which anticoagulant therapy would generally be appropriate.
Patient remoteness was based on residential address according to the Accessibility/Remoteness Index of Australia; 16 socioeconomic status was categorised according to the Index of Relative Socio-economic Disadvantage (in quintiles). 17
Statistical analysis
The cohort was stratified by Aboriginal status and age group (20-59, 60-84 years). We did not include patients over 84 years of age because of their very low number. Patient characteristics were analysed by univariate logistic regression, χ 2 tests, and Wilcoxon signed rank tests for binary, categorical, and continuous variables respectively. Incidence rates were calculated for all outcomes, presented as number per 1000 person-years with 95% confidence intervals (CIs). Unadjusted risks of all stroke, cardiovascular disease and all-cause mortality were estimated by Kaplan-Meier survival analysis. Hazard ratios (with 95% CIs) comparing rates for Aboriginal and non-Aboriginal patients were calculated in Cox proportional hazard models. We undertook a multivariable analysis with progressive adjustment for age (continuous) and sex, remoteness and health insurance status, principal diagnosis of AF, CHA 2 DS 2 -VASc, history of valvular heart disease, chronic kidney disease or chronic obstructive pulmonary disease, and admission year. Assumptions of the Cox proportional hazard models were checked by assessing Schoenfeld and scaled Schoenfeld residuals; no violations were found. Because of the low event numbers, models for haemorrhagic stroke are not presented separately. P < 0.05 was deemed statistically significant. All analyses were undertaken in Stata/ MP 15.1.
Ethics approval
Ethics approval was obtained from the University of Western Australia Human Research Ethics Committee (reference, RA/4/1/5227), the WA Aboriginal Health Research Ethics Committee (reference, 381-01/2011), and the WA Department of Health Human Research Ethics Committee (reference, 2011/89).
Results
During 2000-2012, there were 55 482 index AF hospitalisations of patients aged 20-84 years in WA; 1406 patients (2.5%) were Aboriginal people (825 20-59-year-old patients [7.7% of patients in this age group], 581 60-84-year-old patients [1.3%]). Overall, 599 Aboriginal patients (43%) and 21 908 non-Aboriginal patients (40%) were women; among 20-59-year-old patients, 321 Aboriginal patients (39%) and 2639 non-Aboriginal patients (27%) were women. The mean age of Aboriginal patients was 56.6 years (standard deviation [SD], 13.4 years), of non-Aboriginal patients 69.9 years (SD, 11.7 years); the mean ages of Aboriginal patients in each age group were also lower than for non-Aboriginal patients. More than half the Aboriginal patients resided in remote or very remote locations, and in areas in the two lowest socio-economic status quintiles (Box 1).
The prevalence of major comorbid conditions was higher among Aboriginal than non-Aboriginal patients, and the differences were greater in patients aged 20-59 years (Box 1). The proportion of 20-59-year-old Aboriginal patients with CHA 2 DS 2 -VASc scores of 2 or more (493, 60%) was greater than for non-Aboriginal patients (2151, 22%); among those aged 60-84 years, 507 Aboriginal patients (87%) and 37 026 non-Aboriginal patients (84%) had CHA 2 DS 2 -VASc scores of 2 or more.
The median follow-up time for 20-59-year-old patients was 7.1 years (interquartile range [IQR], 3.8-10 years) for Aboriginal and 6.8 years (IQR, 3.7-10 years) for non-Aboriginal patients; for 60-84-year-old patients, median follow-up was respectively 7.2 years (IQR, 3.7-10 years) and 7.5 years (IQR, 4.1-10 years). , figure 1 ) were significantly greater for Aboriginal than non-Aboriginal patients (log-rank P < 0.001), with larger differences in the 20-59 years age group.
The overall incidence of stroke in the cohort was 23.0 events (95% CI, 22.4-23.6 events) per 1000 person-years. In the 20-59 years age group, the incidence of all stroke was significantly higher 2 Incidence rates of stroke and mortality during the ten years following hospitalisation for atrial fibrillation, by Aboriginal status and age group
Aboriginal

Non-Aboriginal
Incidence rate ratio (95% CI)
Number of patients
Incidence per 1000 person-years (95% CI)
Number of patients
Incidence per 1000 person-years (95% CI)
20-59 years old 825 9862
All stroke 80 (9.7%) 20 (16-25) 366 (3.7%) 6.2 (5.6-6.9) 3.2 (2.5-4.1)
Non-fatal stroke 51 13 (9.7-17) 296 5.0 (4.5-5.6) 2.6 (1. for Aboriginal than non-Aboriginal patients (incidence rate ratio [IRR], 3.2; 95% CI, 2.5-4.1), as was that of non-fatal stroke (IRR, 2.6; 95% CI, 1.8-3.4) (Box 2). The greatest differences in this age group were for fatal (IRR, 5.7; 95% CI, 3.9-8.9) and haemorrhagic stroke (IRR, 4.1; 95% CI, 1.9-6.4). In the 60-84 years age group, incidence of all outcomes (except haemorrhagic stroke) was higher for Aboriginal than non-Aboriginal patients, but the differences were smaller than for the 20-59 years age group, and were similar for all outcomes.
Multivariable-adjusted risks
After full multivariable adjustment, the hazard of all stroke was significantly greater for Progressive adjustment of the Cox models indicated that adjusting for age and sex, AF as principal diagnosis, and CHA 2 DS 2 -VASc score had the greatest impact on aHRs for stroke rates and cardiovascular mortality (Supporting Information, table 2). Adjusting for valvular heart disease, chronic kidney disease, and chronic obstructive pulmonary disease had smaller effects on stroke hazard ratios for either age group.
Discussion
Our whole population cohort study, including more than 55 000 people hospitalised with AF, found marked differences in the risks of stroke and cardiovascular death for Aboriginal and non-Aboriginal Australians, especially among patients under 60 years of age. The relative risks of fatal and haemorrhagic stroke were particularly high for Aboriginal patients in this age group. These differences in risk were largely related to the higher prevalence of prior cardiovascular disease and vascular risk factors among Aboriginal patients under 60.
Differences in stroke and cardiovascular mortality risks
AF is an independent risk factor for ischaemic stroke. 8 While the risk of stroke after AF is higher for many indigenous peoples, 2 comparative data on stroke incidence are limited. The risk of stroke (based on CHA 2 DS 2 -VASc scores) is reported to be twice as high in New Zealand for Māori and Pacific patients under 65 with AF 18 as for non-Māori/non-Pacific patients.
We found that the incidence of stroke (and its subtypes) was higher among Aboriginal than non-Aboriginal patients with AF, particularly among patients under 60 years of age. The higher incidence of AF in Aboriginal than in non-Aboriginal people 4 may contribute to the higher incidence of stroke in Aboriginal Australians. 7, 19 The general prognosis for indigenous people with AF is poor, although long term follow-up data are limited. All-cause mortality at one year among indigenous patients in WA and Canada was 1.5-2 times as high as for non-indigenous patients. 4, 20 We found that the difference in all-cause mortality after AF hospitalisation increases over 10 years, and that most of the difference is associated with cardiovascular causes of death, which in our study accounted for about three-quarters of the mortality burden, consistent with the findings of other population-based studies of patients with AF. 8,21
Reasons for the differences in risk
Cardiovascular risk factor levels and the prevalence of comorbidity are higher among Aboriginal people than other Australians, 22 and the differences are greater in people with AF. 4 In our study, the predicted stroke risk was medium-high (CHA 2 DS 2 -VASc score of at least 2) for about 70% of Aboriginal patients. We found that adjusting for vascular risk factors markedly reduced differences in stroke and cardiovascular mortality risks between Aboriginal and non-Aboriginal people. The higher prevalence of valvular heart disease in Aboriginal people under 60 is probably related to their markedly higher prevalence of rheumatic heart disease. 23 Recent WA data also indicate that multimorbidity was twice as prevalent among Aboriginal people than non-Aboriginal patients with atherothrombotic disease (79% v 39%). 24 Oral anticoagulants reduce the risk of ischaemic stroke and all-cause mortality despite the increased risk of major bleeding, 25 but data on their use by Aboriginal Australians are limited. One study found that more than 70% of Aboriginal patients with AF and CHA 2 DS 2 -VASc scores of 2 or more were not receiving oral anticoagulants. 9 Warfarin was the main oral anticoagulant available during our study period, but adequate monitoring of patients' international normalised ratio (INR) in rural and remote communities is difficult because of remoteness, limitations in service availability and culturally appropriate referral pathways, 26 and family caring responsibilities. Recent Australian guidelines recommend novel oral anticoagulants (NOACs) for Aboriginal people with non-valvular AF because they overcome many of the logistic and clinical barriers associated with warfarin. 27 The higher incidence of haemorrhagic stroke in Aboriginal adults under 60 also indicates that NOACs may be safer options than warfarin, although factors such as poor blood pressure control must be taken into account.
Limitations
We were unable to identify paroxysmal, persistent or chronic AF, or atrial flutter, as ICD coding did not differentiate these subtypes during our study period. However, current clinical guidelines recommend treatment based on stroke risk factors rather than AF type. 27 Our upper age limit of 84 years (fewer than 0.05% of Aboriginal patients were over 84 years of age) may have led to our underestimating the absolute risk of stroke, but our age group-based analyses ensured that the reported relative risks of stroke are valid. Some misclassification of ischaemic and haemorrhagic stroke is probable, as we relied on ICD codes for stroke type. The small number of haemorrhagic strokes precluded robust conclusions about this stroke type.
Medications data were not available in the analysed dataset, so we could not assess the effect of oral anticoagulant therapy on stroke incidence. CHA 2 DS 2 -VASc scores have not been specifically validated in an Aboriginal Australian population.
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Conclusions
The incidence of stroke and cardiovascular mortality are higher among Aboriginal than non-Aboriginal people with AF, and the difference increases with time from hospitalisation, despite evidence of the effectiveness of oral anticoagulants for reducing thrombo-embolic stroke risk. The availability of NOACs provides an opportunity for reducing the risk of stroke for Aboriginal people with AF. Increased screening for cardiovascular disease risk factors and AF in primary care, incorporating new models of care that take cultural factors into account, could improve primary and secondary prevention for Aboriginal people.
